{"protocolSection": {"identificationModule": {"nctId": "NCT00929201", "orgStudyIdInfo": {"id": "0431A-080"}, "secondaryIdInfos": [{"id": "MK-0431A-080", "type": "OTHER", "domain": "Merck protocol number"}, {"id": "2009_607", "type": "OTHER", "domain": "Merck registration number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)", "officialTitle": "An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the Final Marketed Image (FMI) Sitagliptin/Metformin Fixed-Dose Combination (FDC) Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects"}, "statusModule": {"statusVerifiedDate": "2015-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-25", "studyFirstSubmitQcDate": "2009-06-25", "studyFirstPostDateStruct": {"date": "2009-06-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-01-05", "resultsFirstSubmitQcDate": "2010-01-05", "resultsFirstPostDateStruct": {"date": "2010-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-07-22", "lastUpdatePostDateStruct": {"date": "2015-08-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 61, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sita + Met then Sita/Met FDC", "type": "ACTIVE_COMPARATOR", "description": "Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.", "interventionNames": ["Drug: Sitagliptin phosphate/metformin hydrochloride FDC", "Drug: Sitagliptin phosphate", "Drug: Metformin hydrochloride"]}, {"label": "Sita/Met FDC then Sita + Met", "type": "ACTIVE_COMPARATOR", "description": "Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.", "interventionNames": ["Drug: Sitagliptin phosphate/metformin hydrochloride FDC", "Drug: Sitagliptin phosphate", "Drug: Metformin hydrochloride"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin phosphate/metformin hydrochloride FDC", "description": "Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.", "armGroupLabels": ["Sita + Met then Sita/Met FDC", "Sita/Met FDC then Sita + Met"]}, {"type": "DRUG", "name": "Sitagliptin phosphate", "description": "Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.", "armGroupLabels": ["Sita + Met then Sita/Met FDC", "Sita/Met FDC then Sita + Met"]}, {"type": "DRUG", "name": "Metformin hydrochloride", "description": "Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.", "armGroupLabels": ["Sita + Met then Sita/Met FDC", "Sita/Met FDC then Sita + Met"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin", "description": "Serum samples were used to determine the AUC from time 0 to infinity for metformin.", "timeFrame": "Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose"}], "secondaryOutcomes": [{"measure": "Peak Plasma Concentration (Cmax) of Metformin", "description": "Serum samples were used to determine the maximum concentration for metformin.", "timeFrame": "Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* is in good health\n* is a nonsmoker\n* is willing to follow all study guidelines\n\nExclusion Criteria:\n\n* has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant\n* is a nursing mother\n* is unwilling to consume the required high-fat breakfast", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sita + Met Then Sita/Met FDC", "description": "Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg fixed-dose combination (FDC) tablet administered as a single dose during Period 2."}, {"id": "FG001", "title": "Sita/Met FDC Then Sita + Met", "description": "Sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "7-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All randomized participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "61"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.4", "lowerLimit": "18", "upperLimit": "45"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "29"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Centimeters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.9", "lowerLimit": "150.0", "upperLimit": "184.0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73.0", "lowerLimit": "45.9", "upperLimit": "102.3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin", "description": "Serum samples were used to determine the AUC from time 0 to infinity for metformin.", "populationDescription": "All participants who completed and who had pharmacokinetic data available from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg * hr/mL", "timeFrame": "Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose", "groups": [{"id": "OG000", "title": "Sita + Met", "description": "Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose"}, {"id": "OG001", "title": "Sita/Met FDC", "description": "Sitagliptin/Metformin 50 mg/500 mg final marketed image (FMI) FDC tablet administered as a single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.65", "spread": "1.39"}, {"groupId": "OG001", "value": "7.45", "spread": "1.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Least-Squares Mean Ratio calculated as Sitagliptin/Metformin 50/500 mg FDC tablet divided by Sitagliptin 50 mg and metformin 500 mg individual tablets", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The FMI sitagliptin/metformin 50/500 mg FDC tablet and coadministration of corresponding doses of sitagliptin and metformin as individual tablets after consumption of a standard high-fat breakfast will be bioequivalent for metformin based on assessment of the AUC0-\u221e for metformin \\[i.e., the true metformin AUC0-\u221eGMR (sitagliptin/metformin 50/500 mg FDC tablet/co-administration of sitagliptin and metformin as individual tablets will be contained within (0.80, 1.25)\\].", "paramType": "Least-Squares Mean Ratio", "paramValue": "0.97", "ciPctValue": "90", "ciLowerLimit": "0.95", "ciUpperLimit": "1.00"}]}, {"type": "SECONDARY", "title": "Peak Plasma Concentration (Cmax) of Metformin", "description": "Serum samples were used to determine the maximum concentration for metformin.", "populationDescription": "All participants who completed and who had pharmacokinetic data available from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose", "groups": [{"id": "OG000", "title": "Sita + Met", "description": "Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose"}, {"id": "OG001", "title": "Sita/Met FDC", "description": "Sitagliptin/Metformin 50 mg/500 mg FMI FDC tablet administered as a single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "929", "spread": "181"}, {"groupId": "OG001", "value": "887", "spread": "187"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Least-Squares Mean Ratio calculated as Sitagliptin/Metformin 50/500 mg FDC tablet divided by Sitagliptin 50 mg and metformin 500 mg individual tablets", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The FMI sitagliptin/metformin 50/500 mg FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets after consumption of a standard high-fat breakfast will be bioequivalent for metformin based on assessment of the Cmax for metformin \\[i.e., the true metformin Cmax GMR (sitagliptin/metformin 50/500 mg FDC tablet/ co-administration of sitagliptin and metformin as individual tablets will be contained within (0.80, 1.25)\\].", "paramType": "Least-Squares Mean Ratio", "paramValue": "0.95", "ciPctValue": "90", "ciLowerLimit": "0.93", "ciUpperLimit": "0.98"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 24 days (including 14 days after administration of study drug in the last treatment period)", "description": "All participants as treated defined as all participants who received at least one dose of study drug", "eventGroups": [{"id": "EG000", "title": "Sita + Met", "description": "Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 2, "otherNumAtRisk": 60}, {"id": "EG001", "title": "Sita/Met FDC", "description": "Sitagliptin/Metformin 50 mg/500 mg FMI FDC tablet administered as a single dose", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 6, "otherNumAtRisk": 61}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 61}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}